Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1Phase 1 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1Lymphoid 1

Conditions

Prostatic Neoplasms 25Lymphoma, Large B-Cell, Diffuse 23Burkitt Lymphoma 16Lymphoma 13Precursor Cell Lymphoblastic Leukemia-Lymphoma 10Lymphoma, Non-Hodgkin 9Lymphoma, Follicular 9Neoplasm Metastasis 7Lymphoma, Mantle-Cell 7Lymphoma, B-Cell, Marginal Zone 6Lymphoma, B-Cell 6Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 5Multiple Myeloma 5Lymphoma, T-Cell, Peripheral 5Leukemia 5Recurrence 4Neoplasms 4Lymphoma, T-Cell 4Leukemia, Lymphocytic, Chronic, B-Cell 4Hodgkin Disease 4Neoplasms, Plasma Cell 3Myelodysplastic Syndromes 3Lymphoma, Large-Cell, Immunoblastic 3Lymphoma, Large-Cell, Anaplastic 3Leukemia, Myeloid, Chronic-Phase 3Leukemia, Myeloid, Accelerated Phase 3Leukemia, Biphenotypic, Acute 3Carcinoma, Non-Small-Cell Lung 3Thrombocythemia, Essential 2Primary Myelofibrosis 2

Interventions

Imatinib Mesylate 18Dasatinib 12Cyclophosphamide 11fludarabine phosphate 9nilotinib 8fludarabine 7Sirolimus 6ruxolitinib 5Tacrolimus 5Mycophenolic Acid 5Cytarabine 5Azacitidine 5Whole-Body Irradiation 4Ipilimumab 4Busulfan 4Bortezomib 4thymoglobulin 3bosutinib 3belinostat 3aldesleukin 3Specimen Handling 3Nivolumab 3Interleukin-2 3Granulocyte Colony-Stimulating Factor 3Clofarabine 3CTLA-4 Antigen 3Antilymphocyte Serum 3AP 1903 reagent 3zileuton 2tozasertib 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Leukemia, Myelogenous, Chronic, BCR-ABL Positive × Prednisone × Clear all
NCT03595917 2025-11-04

ABL001 + Dasatinib + Prednisone + Blinatumomab in BCR-ABL+ B-ALL or CML

Dana-Farber Cancer Institute

Phase 1 Recruiting
40 enrolled
LymphoidMyeloidOther hematologic neoplasm

Burkitt Lymphoma, Leukemia, Myelogenous, Chronic, BCR-ABL Positive

Data powered by HemOnc (CC BY 4.0) Colophon âš¡